Cingulate therapeutics headquarters
WebJun 15, 2024 · Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products … WebJun 16, 2024 · Cingulate Therapeutics, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment …
Cingulate therapeutics headquarters
Did you know?
WebCingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate Therapeutics is registered under the ticker NASDAQ:CING . Their stock opened with $6.00 in its Dec 8, 2024 IPO. WebApr 10, 2024 · Analyst Forecast. According to 10 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 508.12% from the latest price.
WebPrairie Village, Kansas, United States 844 followers 500+ connections Join to connect Cingulate Therapeutics About I have extensive experience … WebCingulate Inc. 1,061 followers. 2mo. Today we announce our Q3 2024 financial results and provided a clinical and business update, including updated study timelines for our lead …
WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member … WebJun 24, 2024 · Virtual. We are pleased to invite you to a virtual call series highlighting the next generation of life sciences private companies from Monday, June 29 th – Thursday, July 2 nd, 2024. We will be hosting the companies for 35 minute presentations with time for Q&A over the four days.
WebDec 8, 2024 · Cingulate Therapeutics (CTx) is a privately held, clinical-stage biopharmaceutical company focused on the development of products for the treatment …
WebJun 15, 2024 · KANSAS CITY, Kan., June 15, 2024 /PRNewswire/ -- Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on... florist lake havasu city azWebCingulate Therapeutics is headquartered in Mission, 1901 W 47th Pl, United States, and has 2 office locations. greaves of desolationWebCingulate Therapeutics is a biopharmaceutical company developing products for the treatment of central nervous system and neurobiological disorders. greaves musicWebApr 3, 2024 · Cingulate Therapeutics doesn't have any recent trademark applications, indicating Cingulate Therapeutics is focusing on its existing business rather than … greaves niagara on the lakeWebJul 11, 2024 · 11 Jul 2024 Cingulate CEO: $7.5M fundraising round will help drive pharma growth in KC. A former Marion Laboratories employee, Shane Schaffer’s goal from the … greaves of aweWebWhere is Cingulate Therapeutics 's headquarters? Cingulate Therapeutics is located in Morristown, New Jersey, United States. Who … florist lake waccamaw ncWebMr. Peter Werth serves as Board Member at Cingulate Therapeutics. He is the Founder and also serves as Chief Executive Officer at Werth Ventures. He serves as Board Member at Alopexx Enterprises. He is the Owner & serves as the Chief Executive Officer & President at Chemwerth. He also served as a board member at InnoPharma. florist lake orion michigan